About 25 years ago the addition of the combination of mitoxantrone + prednisone to androgen deprivation therapy (ADT) was the first form of chemotherapy ever approved for the treatment of metastatic, castration-resistant prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "high risk", ADT, androgen, deprivation, mitoxantrone, outcome, prednisone, survival | 3 Comments »
A group of Italian clinicians and researchers have reported that low-dose abiraterone acetate along with very low-dose prednisone appears to be both effective and safe in the treatment of elderly patients between 85 and 93 years of age with castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, dose, elderly, food, prednisone | 9 Comments »
A report on a Phase II study from the Department of Defense-funded Prostate Cancer Clinical Trials Consortium has suggested that ixabepilone + mitoxantrone + prednisone may have clinically significant activity as a form of second-line chemotherapy in the management of men with docetaxel-refractory, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ixabepilone, mCRPC, mitoxantrone, prednisone, taxane-refractory | 2 Comments »
In today’s (slightly belated) news reports, we comment on studies dealing with:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: CRPC, docetaxel, high-risk patients, hypertension, prednisone, RALP, risk, robot-assisted laparoscopic prostatectomy | Leave a comment »
In today’s news reports you will find items on:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: EBRT, external beam radiation therapy, mitoxantrone, obesity, outcome, prednisone, PSA level | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 